Actively Recruiting
Active Oxygen Releasing Gel With Photodynamic Therapy in Treating Stage III Periodontitis
Led by Alexandria University · Updated on 2026-04-28
42
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Periodontitis is a serious gum disease that can damage the tissues supporting the teeth. The standard treatment is scaling and root planing of the teeth and roots. However, in some patients, this treatment alone may not fully control inflammation and harmful bacteria. This study aims to evaluate whether adding an active oxygen-releasing gel, with or without photodynamic therapy, improves treatment outcomes in patients with stage III periodontitis. The oxygen-releasing gel is applied to the gums and releases oxygen, which may help reduce harmful bacteria. Photodynamic therapy uses a light source together with a special dye to target and destroy bacteria and improve gingival health. In this randomized clinical trial, 42 patients with stage III periodontitis will be divided into three groups. One group will receive standard scaling and root planing (SRP) plus the oxygen-releasing gel. A second group will receive standard scaling and root planing (SRP)plus the gel and photodynamic therapy. The third group will receive standard scaling and root planing(SRP) only. Gum health will be evaluated by measuring gingival index, bleeding index, pocket depth, and supra crestal tissue attachment level at the start of the study and after one and three months. Microbiological samples from periodontal pockets will also be used to assess levels using quantitative Polymerase Chain Reaction (qPCR) for relative abundance of Treponema denticola and Porphyromonas gingivalis bacteria related to periodontal disease.
CONDITIONS
Official Title
Active Oxygen Releasing Gel With Photodynamic Therapy in Treating Stage III Periodontitis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients diagnosed with stage III periodontitis
- Residual periodontal pocket depth of 4 mm or more and clinical attachment level of 5 mm or more with bone loss reaching the middle third of the root or beyond on X-rays
- Bleeding on probing at least four sites at baseline
- No periodontal treatment received in the 3 months before examination
- Patients of any gender aged between 30 and 70 years
You will not qualify if you...
- Current smokers or users of other harmful habits such as pipe or vape smoking
- Patients with systemic conditions that may affect periodontal therapy outcomes, such as diabetes
- Patients who have used any local or systemic anti-inflammatory drugs or antibiotics in the last 6 months
- Pregnant or breastfeeding women
- Patients with parafunctional habits
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Faculty of Dentistry, Alexandria University
Alexandria, Bab Sharq, Egypt, 21578
Actively Recruiting
Research Team
A
Aya Abdelmawla, BDS
CONTACT
A
Aliaa Gamaleldin Aboulela, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here